Elanco Animal Health Incorporated (NYSE:ELAN) Director Purchases $102,000.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares in the company, valued at $1,136,881.80. The trade was a 9.86 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Friday, March 7th, Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock. The stock was acquired at an average cost of $10.90 per share, for a total transaction of $109,000.00.

Elanco Animal Health Price Performance

ELAN stock opened at $10.32 on Friday. Elanco Animal Health Incorporated has a 52-week low of $10.03 and a 52-week high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of 25.79, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The business has a fifty day moving average of $11.52 and a two-hundred day moving average of $12.81.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.08 earnings per share. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Large investors have recently made changes to their positions in the stock. CoreCap Advisors LLC acquired a new stake in Elanco Animal Health in the 4th quarter valued at approximately $29,000. AM Squared Ltd purchased a new position in shares of Elanco Animal Health during the third quarter worth $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health in the third quarter valued at $35,000. Farther Finance Advisors LLC raised its holdings in shares of Elanco Animal Health by 158.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after buying an additional 2,044 shares during the period. Finally, Venturi Wealth Management LLC lifted its stake in Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after acquiring an additional 1,601 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on ELAN shares. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Leerink Partners started coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target for the company. Stifel Nicolaus lowered their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. UBS Group dropped their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Finally, Piper Sandler reduced their price target on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.